Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...

Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We recently compiled a list of the 10 Best Cancer Stocks To Buy Now ... It generates revenue mainly from pharmaceutical products and vaccines, with a significant portion coming from its cancer drug ...

AstraZeneca and Merck & Co have cemented their lead in the ... ovarian and breast cancer – which are already on Lynparza’s list of approved indications. Use in ovarian and breast cancer ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

When a pharmaceutical company such as Merck has an extremely successful product such as Keytruda, it can be both a blessing and a curse. Keytruda is a significant source of revenue growth for the ...